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Abstract  
Background: Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers. 
There are many published studies of cost-effectiveness analyses of licensed treatments, but no study 
has compared these studies or their approaches simultaneously.  
Objective: To investigate the methodology used in published economic analyses of licensed 
interventions for previously treated advanced/metastatic NSCLC in patients without anaplastic 
lymphoma kinase or epidermal growth factor receptor expression.  
Methods:  A systematic review was performed, including a systematic search of key databases (e.g. 
MEDLINE, EMBASE, Web of Knowledge, Cost-effectiveness Registry) limited from 01 January 2001 to 
26 July 2019. 
Two reviewers independently screened, data extracted and quality appraised studies identified. The 
reporting quality of the studies was assessed by using the Consolidated Health Economic Evaluation 
Reporting Standards and the Philips’ checklists. 
Results: Thirty-one published records met the inclusion criteria which corresponded to 30 individual 
cost-effectiveness analyses. Analytical approaches included partitioned survival models (n=14), 
state-transition models (n=7) and retrospective analyses of new or published data (n=8). Model 
structure was generally consistent, with pre-progression, post-progression and death health states 
used most commonly. Other characteristics varied more widely, including the perspective of 
analysis, discounting, time horizon, usually to align with the country that the analysis was set in. 
Conclusions: There are a wide range of approaches in the modelling of treatments for advanced 
NSCLC, however the model structures are consistent. There is variation in the exploration of 
sensitivity analyses, with considerable uncertainty remaining in most evaluations. Improved 
reporting is necessary to ensure transparency in future analyses. 
 
 
Key points for decision makers 
The structure of the models was consistent with little deviation from the pre-progression, post-
progression and death health states.  
The modelling of overall survival is routinely one of the most influential factors on the cost-
effectiveness conclusions but is often associated with considerable uncertainty.  
Studies should report with greater transparency their methods for extrapolating survival curves to 
reduce bias in cost-effectiveness analyses.  
There is insufficient evidence to conclude which treatment is the most cost-effective and further 
research is necessary. 
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1. Introduction 
Lung cancer is one of the most commonly diagnosed cancer and the leading cause of cancer-related 
deaths globally [1], with non-small lung cancer (NSCLC) accounting for 85 to 90% of all forms of lung 
cancer [2]. The development of targeted therapies and immunotherapies promises to fill some of 
the unmet need for the treatment of advanced/metastatic NSCLC. To date, 13 agents have a label 
indication for the treatment of advanced/metastatic NSCLC in patients after failure to first-line 
chemotherapy (docetaxel, pemetrexed, ramucirumab with docetaxel, erlotinib, nintedanib with 
docetaxel, afatinib, nivolumab, pembrolizumab, atezolizumab, crizotinib, ceretinib, gefitinib and 
osimertinib), four of which are targeted therapies for patients with anaplastic lymphoma kinase 
expression (ALK+) or epidermal growth factor receptor expression (EGFR+) disease. In the absence of 
head-to-head comparison studies between most of the licensed drugs for this specific population, 
we showed in a previous systematic review with network meta-analyses that the three recent 
immune checkpoints inhibitors namely, nivolumab, pembrolizumab and atezolizumab exhibited 
superior benefit/risk balance compared to other licensed drugs [3]. The same was found in a 
secondary analysis of trials using restricted-mean-survivals and parametric modelling to measure 
effectiveness [4]. 
However, due to the substantial costs of these drugs, their use is raising concerns because of the 
high economic impact these drugs are likely to have on health systems [5]. This advocates for the 
use of economic modelling to be conducted in order to comprehensively compare these licensed 
drugs on both the cost and effectiveness dimensions.  
Prior to this comprehensive cost-effectiveness evaluation, we aimed to undertake a systematic 
review of existing economic evaluations relating to previously treated NSCLC drugs to synthesise 
existing evidence, specifically focusing on model-based economic analyses. This first stage is 
required because of the anticipated complexity of the cost-effectiveness modelling of NSCLC drugs. 
In this systematic review, we have summarised the modelling techniques, clinical inputs, resource 
use and costs, and outcome measures used in the analyses, and suggested key issues to consider in 
developing further cost-effectiveness models. Previous systematic reviews comparing the clinical-
effectiveness of interventions for NSCLC have been published [3, 6], but our literature search did not 
identify any systematic reviews with a focus on cost-effectiveness evidence. This paper addresses 
this gap in the literature. 
2.  Methods 
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The protocol for this systematic review was registered on the PROSPERO international prospective 
register of systematic reviews [7].  
2.1. Search strategy 
A literature search of published economic evaluations was performed, following the PRISMA 
(Preferred Reporting Items for Systematic review and Meta-Analysis) guidelines [8]. Electronic 
databases (MEDLINE, EMBASE (Ovid), Cochrane Library (Wiley), , Science Citation Index (Web of 
Knowledge), Research Papers in Economics (RePEC) and the Cost-Effectiveness Analysis (CEA) 
Registry), and the National Institute of Health and Care Excellence (NICE) website were searched for 
relevant literature. We also performed citation searches and searched reference lists of relevant 
included studies, and any previously published systematic reviews. The search was limited to studies 
published in the English language from 1 January 2001 up to 26 July 2019. This start point was chosen 
because it corresponds to the year that docetaxel was appraised by NICE for NSCLC, docetaxel being 
the first agent that was labelled for this indication and was established as the standard of care in 
second-line therapy [9]. The search strategy combined NSCLC terminology with economic terms. A 
copy of the search terms is available in the supplementary information.  
2.2. Study selection/Inclusion and exclusion criteria 
All citations retrieved were screened independently by two reviewers (DG and PA) at title/abstract 
stage, of which potentially relevant records were further examined at full-texts. Any disagreements 
between the reviewers were resolved by consensus or recourse to a third reviewer (XA). We 
examined original papers, technology appraisal guidance, letters, editorials and meeting abstracts. 
Studies were considered to be relevant if the study examined at least one treatment with label 
indication for advanced/metastatic NSCLC as of January 2018 (docetaxel, pemetrexed, ramucirumab 
with docetaxel, erlotinib, nintedanib with docetaxel, afatinib, nivolumab, pembrolizumab, 
atezolizumab, best supportive care alone or in combination with a drug of interest. We excluded the 
four targeted therapies (crizotinib, ceretinib, gefitinib and osimertinib. To be included, studies 
should have used an economic analysis to compare treatments licensed for adults with 
advanced/metastatic NSCLC, and meeting the following characteristics: 
 Non-squamous (adenocarcinoma, large cell), or squamous histology  
 ALK expression either predominantly negative or 100% negative  
 EGFR expression either predominantly negative or 100% negative  
 Patients who experienced failure to prior first line chemotherapy (i.e., those receiving 
second line treatment and beyond) 
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We excluded studies that included people with ALK+ and/or EGFR+ expression, as according to 
current practices, these patients are routinely offered targeted therapies. 
2.3. Data extraction & synthesis 
Two reviewers (DG & PA) each extracted information from half of the studies and further cross-
checked each other’s extractions. Any disagreements were resolved by discussion or by recourse to 
a third reviewer (XA). Information was extracted on study details (title, author and year of study), 
baseline characteristics (population, intervention, comparator and outcomes), methods (study 
perspective, time horizon, discount rate, measure of effectiveness, units of currency, conversions, 
assumptions and analytical methods), results (study parameters, base-case and sensitivity analysis 
results), discussion (study findings, limitations of the models and generalisability), other (source of 
funding and conflicts of interests), overall comments and conclusions (author’s and reviewer’s). A 
template of the extraction form is provided in the supplementary information. Information extracted 
from the included studies were summarised and presented in Table 1. Due to the nature of 
economic analyses (different aims/objectives, study designs, populations, and methods) these 
findings from individual studies were compared narratively, and recommendations for future 
economic analyses are discussed. 
2.4 Critical appraisal and quality assessment tools 
The reporting quality of the studies was assessed against the Consolidated Health Economic 
Reporting Standards (CHEERS) [10] and the Philips’ checklist [11], respectively. PA and DG critically 
appraised half of the final list of included studies, with XA independently verifying the accuracy of 
the information. Any differences were resolved by discussion or by a fourth assessor (HM).   
3.  Results  
3.1 Search results 
Details of the literature search and review process can be found in the PRISMA flow chart [12] in 
Figure 1. Following screening of the 837 identified records, 612 were screened at title and abstract 
and 54 were assessed at full text level, with 30 records included in the review, representing 30 
separate studies. 
 
  
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
n = 835 
Sc
re
e
n
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Records screened (after duplicates 
removed)  
n = 612 
Full-text records assessed for eligibility  
n = 54 
Full-text records 
excluded  
n = 24 
 
Full-text records included in qualitative 
synthesis  
n = 30 
Studies represented in qualitative 
synthesis 
n = 30 
 
Records excluded at 
title and abstract 
level  
n = 558 
Duplicate records 
removed  
n = 225 
Additional records identified 
through other sources  
n = 2 
Records identified (total before 
deduplication)  
n = 837 
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Table 1: Summary characteristics and results of included studies  
Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Leighl et al., 
2002, Canada 
[13] 
Docetaxel 
(100mg/m2 and 
75mg/m2) vs 
BSC 
Patients with 
advanced NSCLC 
who had 
previously 
received one or 
more cisplatin-
based 
chemotherapy, 
ECOG ≤ 2. 
Retrospectiv
e CEA of a 
clinical trial, 
National 
Health Care 
System, No 
discounting 
was applied. 
Data 
from 20 
months 
of trial 
follow-
up 
Cost per 
LYG  
CEA conducted 
retrospectively 
using trial data 
None ICER of 
docetaxel 
(combined) vs 
BSC =  
CAD$ 
57,750/LY 
ICER of 
docetaxel 
(75mg/m2) = 
CAD$ 31,780 
/QALY 
Survival is 
most 
influential 
parameter on 
cost-
effectiveness 
results 
Holmes et al., 
2004, UK [14] 
Docetaxel vs 
BSC 
NSCLC patients 
who had 
received prior 
treatment with 
platinum 
containing 
chemotherapy  
The disease 
severity of 
patients is 
unclear. 
Retrospectiv
e analysis of 
cost and 
survival data, 
NHS 
perspective, 
No 
discounting 
was applied. 
2 years Cost per 
LYG 
CEA conducted 
retrospectively 
Zero costs 
assumed for 
BSC arm. 
ICER = £ 
13,863/LY 
Mean survival 
was most 
influential on 
cost/LY 
NICE 
Technology 
Appraisal 124 - 
Pemetrexed 
Eli Lilly 
2006, UK [15] 
Pemetrexed vs 
docetaxel  
(also compared 
to BSC 
indirectly) 
Adults with 
locally advanced 
or metastatic 
NSCLC and had 
relapsed after 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
3 years Cost per 
LYG; Cost 
per QALY 
gained 
CEA using a Markov 
model with four 
main health states: 
Stable, Response, 
Progressive or 
Death, 21 day cycle 
Patients 
could only 
die from 
progressive 
health 
state, or via 
Company ICER 
vs docetaxel:  £ 
7,097/LY and £ 
18,672/QALY   
Company ICER 
vs BSC:  £ 
Time horizon, 
drug costs and 
survival 
modelling 
were all 
influential 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
previous 
chemotherapy 
febrile 
neutropenia 
Patients 
remained 
on 
treatment 
for up to 6 
cycles. 
10,418/LY and 
£ 16,458/QALY 
ERG base case 
of £ 
458,333/QALY 
vs docetaxel 
Araujo et al., 
2008, Portugal 
[16] 
Erlotinib vs 
docetaxel vs 
pemetrexed vs 
BSC 
Patients with 
advanced or 
metastatic 
disease NSCLC 
(IIIA, IIIB, IV) 
who have failed 
at least one 
prior 
chemotherapy 
Model-based 
economic 
analysis, NHS 
perspective,  
5% discount 
rate 
2 years Cost per 
LYG; Cost 
per QALY 
gained 
CEA  using a 
partitioned survival 
model with three 
states (progression-
free, post-
progression and 
death), 1 month 
cycle 
Equal 
efficiacy 
assumed for 
erlotinib, 
docextaxel 
and 
pemetrexed 
for PFS and 
OS. 
Erlotinib 
dominated 
docetaxel and 
pemetrexed. 
ICER vs BSC 
was € 
161,742/QALY 
and € 
70,424/LY 
PSA results 
were € 
161,356/QALY 
and € 
71,152/LY 
Choice of 
parametric 
curve was 
influential 
along with 
later line 
treatments. 
Carlson et al., 
2008, USA [17] 
Erlotinib vs 
docetaxel vs 
pemetrexed 
Patients with 
advanced (stage 
III—IV) NSCLC  
who failed at 
least one 
platinum-based 
chemotherapy 
Model based 
economic 
analysis, US 
health 
system 
perspective, 
2 years Cost per 
QALY 
gained 
Decision analytic 
model, with three 
health states 
(progression free, 
post-progression 
and death) 
Equal 
efficiacy 
assumed for 
erlotinib, 
docextaxel 
and 
pemetrexed 
Erlotinib 
dominated 
both docetaxel 
and 
pemetrexed. 
pemetrexed vs 
docetaxel ICER 
Most 
influential on 
cost and 
QALYs were 
time spent in 
PFS state 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
3% discount 
rate 
for PFS and 
OS. 
was US$ 
1,743,369/QAL
Y 
McLeod et al., 
2009, UK [18] 
Erlotinib vs 
docetaxel 
Patients with 
locally advanced 
or metastatic 
(stage IIIB/IV) 
NSCLC 
Model-based 
economic 
analysis, NHS 
and PSS, 
discount rate 
not reported. 
Not 
reported 
Cost per 
QALY 
gained 
CEA using a Markov 
model with three 
health states 
(progression free, 
post-progression 
and death), cycle 
length unknown 
Equivalent 
OS assumed 
The company’s 
results 
suggests that 
erlotinib 
dominated 
docetaxel, with 
a 0.68 
probability of 
being cost-
effective at a 
willingness-to-
pay threshold 
of £30,000 per 
QALY gained. 
However, 
under new 
assumptions by 
the ERG, the 
base-case ICER 
was 
approximately 
£ 52,000 per 
QALY. The 
ERG’s PSA 
results showed 
that there was 
Not reported 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
a 0.44 
probability of 
being cost-
effective 
Lewis et al., 
2010, UK [19] 
Erlotinib vs 
docetaxel 
Patients with  
previously 
treated stage 
IIIB/IV NSCLC 
Model-based 
economic 
analysis, NHS 
and PSS, 
3.5% 
discount rate 
2 years Cost per 
QALY 
gained 
CEA using a Markov 
model with three 
health states 
(progression-free, 
progression and 
dead), 1 month 
cycle 
Equivalent 
OS assumed 
Erlotinib 
dominated 
docetaxel. 
Incremental 
costs were 
approximately -
£ 200 and 
expected to 
yield 0.032 
more QALYs. At 
a willingness-
to-pay 
threshold of £ 
30,000 per 
QALY, erlotinib 
had a 0.70 
probability of 
being cost-
effective 
Reducing the 
cost of 
docetaxel 
administration
, the cost of 
progression 
and utility 
score for PFS 
for docetaxel 
had the 
greatest 
impact to the 
results 
Asukai et al., 
2010, Spain 
[20] 
Pemetrexed  vs  
docetaxel  
Patients with 
previously 
treated 
advanced-stage 
(stage III or IV) 
with 
Model-based 
economic 
analysis, 
health care 
provider, 3% 
discount rate  
3 years Cost per 
LYG; Cost 
per QALY 
gained 
CEA using a Markov 
model with three 
health states: 
stable, response 
and progression, 21 
day cycle  
Constant 
hazard rate 
assumed for 
OS 
Pemetrexed 
compared to 
docetaxel 
resulted in an 
ICER of 
approximately 
Overall 
survival 
appeared to 
be the main 
driver of the 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
predominantly 
non-squamous 
histology and 
are eligible for 
second line 
treatment 
€ 24,000 per 
QALY and € 
17,200 per LY.  
Results from 
the PSA 
showed that 
pemetrexed 
had a 0.62 
probability of 
being cost-
effective than 
docetaxel at a 
willingness-to-
pay threshold 
of € 30,000 per 
QALY. 
economic 
model 
Cromwell et 
al., 2011, 
Canada [21] 
Erlotinib vs 
docetaxel 
Patients with 
stage IIIb/IV 
advanced NSCLC 
receiving 
second-line 
treatment 
Retrospectiv
e CEA, British 
Columbia 
health care, 
discount rate 
not applied. 
31 
months 
Costs 
and LY 
CEA conducted 
retrospectively 
None No ICER 
presented as 
only 1 day 
difference in 
mean OS and 
CAD$ 2,891 
cost difference 
Unclear 
Vergnenegre 
et al., 2011, 
France [22] 
Docetaxel 
(75mg/m2 as a 
one-hour 
intravenous 
infusion) vs BSC 
(pemetrexed) 
Adults >18 
years, with at 
least one 
measurable 
lesion, stage IIB 
or IV NSCLC, 
Economic 
analysis 
alongside a 
randomised, 
prospective 
multicentre 
2 year 
trial 
Cost per 
QALY 
gained 
CEA with 7 health 
states: responding 
on 
chemotherapy, with 
or without grade 
None Results showed 
that docetaxel 
dominated 
pemetrexed  
Results from 
the one-way 
sensitivity 
analysis 
showed that 
changes to key 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
ECOG score 0-2, 
and progressive 
disease after 
chemotherapy 
for metastatic 
disease 
study, 
payer’s 
perspective, 
discount rate 
not applied 
3/4 AEs; stable, 
with or 
without grade 3/4 
AE; progression, 
with or without 
grade 3/4 
AE; and death, cycle 
length unknown 
parameter did 
not have an 
impact on the 
results 
Cromwell et 
al., 2012, 
Canada [23] 
Erlotinib vs 
symptom 
management 
Patients with 
previously 
treated stage 
IIIB/IV advanced 
NSCLC 
Retrospectiv
e CEA, British 
Columbia 
health care, 
discount rate 
not applied  
Not 
applicabl
e 
Cost per 
LYG 
CEA conducted 
retrospectively 
None An estimated 
ICER of 
approximately 
CAD$ 36,800 
per LYG. 
PSA results 
showed that at 
a willingness-
to-pay-
threshold of 
CAD$ 50,000, 
CAD$ 100,000 
and CAD$ 
200,000/LY, 
erlotinib is 
likely to be 
cost-effective 
in 58%, 79% 
and 95% of the 
simulations, 
respectively. 
Sensitivity 
analysis 
showed that 
all parameters 
impacted the 
base-case ICER 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Greenhalgh et 
al., 2015, UK 
[24] 
Erlotinib vs 
docetaxel or 
best supportive 
care 
People aged ≥ 
18 years with an 
ECOG PS score 
between 0-3, 
with 
documented 
evidence of 
NSCLC. 
Model-based 
economic 
analysis, NHS 
and PSS, 
3.5% 
discount rate 
Company
: 6-year  
 
ERG: 5-
year 
Cost per 
QALY 
gained 
CEA using a 
partitioned survival 
model with three 
health states 
(progression-free, 
progressed and 
dead);  
AG model includes 
four health states 
(advanced/metastat
ic NSCLC progressed 
after first-line 
chemo, 
progression-free 
after second-line 
chemotherapy, post 
progression and 
dead), 1 week cycle 
Utility 
scores are 
not 
treatment 
specific 
Company 
results: 
erlotinib 
compared to 
BSC has an 
ICER of 
approximately 
£ 51,000/QALY 
gained in EGFR 
unknown 
population.  
AG for EGFR 
negative 
population, 
concluded that 
docetaxel 
dominated 
erlotinib.  
AG ICER for 
erlotinib vs BSC 
was £ 
54,687/QALY in 
EGFR unknown 
population. 
Not reported 
by the 
company.  
 
AG stated that 
using 
alternative 
British 
National 
Formulae 
pricing for 
docetaxel was 
the most 
influential 
parameter 
NICE 
Technology 
Appraisal 347 
–Nintedanib, 
Nintedanib vs 
docetaxel 
People with 
locally advanced 
or metastatic 
NSCLC whose 
disease 
Model-based 
economic 
analysis, NHS 
and PSS, 
15 years Cost per 
QALY 
gained 
CEA using a 
partitioned survival 
model with three 
health states 
(progression-free, 
None Company 
results vs 
docetaxel: £ 
46,580/QALY 
Company 
reported that 
changes to the 
survival 
modelling 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Boehringer 
Ingelheim, 
2015, UK [25] 
progressed 
following 
platinum-based 
treatment 
3.5% 
discount rate 
progressed and 
dead), 3 week cycle 
 
ERG results: £ 
56,804/QALY 
were 
influential on 
ICER. 
ERG reported 
post-
progression 
utility values 
were 
influential 
Bosch et al., 
2016, Spain 
[26] 
Nintedanib plus 
docetaxel vs 
placebo plus 
docetaxel 
Adults with 
locally 
advanced, 
metastatic or 
locally recurrent 
NSCLC, with 
adenocarcinom
a histology after 
treatment with 
first-line 
chemotherapy 
Economic 
analysis 
alongside a 
RCT, NHS, 
discount rate 
is not applied  
Approx. 
36 
months 
Cost per 
LYG 
CEA of a trial. None PFS: Results 
showed that 
nintedanib + 
docetaxel 
compared to 
placebo + 
docetaxel has 
an ICER of 
approximately 
€ 134,300/LY. 
Based on a 25% 
discount on the 
cost of 
nintedanib 
resulted in an 
ICER of 
approximately 
€ 106,300/ LY 
  
Not reported 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Adenocarcino
ma OS: Results 
showed that 
nintedanib + 
docetaxel 
compared to 
placebo + 
docetaxel has 
an ICER of 
approximately 
€ 40,900/LY. 
Based on a 25% 
discount on the 
cost of 
nintedanib 
resulted in an 
ICER of 
approximately 
€ 32,400/LY 
Matter-
Walstra et al., 
2016, 
Switzerland 
[27] 
Nivolumab vs 
docetaxel 
Advanced Non-
squamous 
NSCLC patients 
with failure to at 
least one prior 
therapy 
Model based 
economic 
analysis, 
National 
Healthcare 
system, No 
discounting 
was applied 
“lifelong
” 
Cost per 
QALY 
gained 
CEA using a Markov 
model with three 
health states 
(progression-free, 
progression and 
dead) with monthly 
cycles, 1 month 
cycle 
PFS and OS 
hazard rates 
were 
assumed 
constant 
over time. 
Treatment 
received 
until 
ICER  
CHf 
177,478/QALY 
Of the 
investigated 
variables, 
utility scores 
of the health-
states were 
the most 
influential on 
the ICER 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
disease 
progression. 
Goeree et al., 
2016, Canada 
[28] 
Nivolumab vs 
docetaxel vs 
erlotinib 
Patients with 
advanced 
squamous 
NSCLC who have 
been previously 
treated 
Model based 
economic 
analysis, 
Public 
Healthcare 
System, 5% 
discount rate  
10 years Cost per 
QALY 
gained 
and cost 
per LYG. 
CEA using a 
partitioned survival 
model and Markov 
model were used. 
Both had three 
health states 
(progression-free, 
post-progression 
and death), 4 week 
cycle 
Utility 
values were 
not 
treatment 
specific. 
Treatment 
received 
until 
disease 
progression. 
PSM results 
ICER vs 
docetaxel 
CAD$ 
151,560/QALY 
ICER vs  
erlotinib CAD$ 
140,601 
Markov results: 
ICER vs 
docetaxel 
CAD$ 
152,239/QALY 
ICER vs 
erlotinib 
CAD$ 
141,838/QALY 
 
PSA ICERs 
Vs docetaxel  
CAD$ 
158,154/QALY 
Vs erlotinib 
CAD$ 
145,773/QALY 
Utility values 
were most 
influential on 
ICER, of the 
investigated 
parameters 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
NICE 
Technology 
Appraisal 403 
– 
Ramucirumab, 
Eli Lilly, 
2016, UK [29] 
Ramucirumab 
plus docetaxel 
vs docetaxel 
Adults with 
locally advanced 
or metastatic 
NSCLC  whose 
disease has 
progressed after 
platinum-based 
chemotherapy 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
15 years Cost per 
QALY 
gained 
CEA  using a 
partitioned survival 
model with 3 states: 
pre-progression, 
post-progression 
and death, 21 day 
cycle 
Treatment 
received 
until 
disease 
progression 
or 
unacceptabl
e toxicities.  
Proportiona
l hazards 
was 
assumed for 
OS. 
Company base-
case vs 
docetaxel: £ 
194,919/QALY 
 
ERG ICER was £ 
175,000/QALY 
 
ICER was most 
sensitive to 
price of 
interventions, 
discount rate, 
the time on 
treatment and 
choice of 
parametric fit 
Huang et al., 
2017, USA [30] 
Pembrolizumab 
2mg/kg vs 
docetaxel 
Adults (>18 
years) with 
advanced NSCLC 
who 
experienced 
diseased 
progression 
following first-
line treatment 
with a platinum-
based therapy 
Model-based 
economic 
analysis, 
third-party 
payer, 3% 
discount rate 
20 years Cost per 
LYG; Cost 
per QALY 
gained 
CEA with 
partitioned-survival 
model with three 
health states, 1 
week cycle 
Equal OS 
hazard rate 
assumed for 
both 
treatments 
beyond 6.5 
years. 
Pembrolizuma
b is expected 
to cost 
approximately 
US$ 160,500 
more than 
docetaxel and 
expected to 
yield 1.18 LYs 
equating to an 
ICER of 
approximately 
US$ 135,600 
per LY 
 
Sensitivity 
analysis 
showed that 
extrapolation 
of overall 
survival, time-
on-treatment 
for 
pembrolizuma
b, and utilities 
for time 
greater or 
equal to 360 
days from 
death had the 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Pembrolizuma
b is expected 
to yield 0.95 
QALYs equating 
to an ICER of 
approximately 
US$ 168,600 
per QALY 
greatest 
impact to the 
ICER 
Pignata et al., 
2017, France 
[31] 
Afatinib vs 
erlotinib 
Squamous 
advanced NSCLC 
patients who  
experienced 
disease 
progression 
during or 
following 
treatment with 
platinum-based 
chemotherapy 
Model based 
economic 
analysis, 
NHS, 4% 
discount rate 
10 years Cost per 
QALY 
gained 
Partitioned survival 
analysis with three 
health states:  pre-
progression, post-
progression and 
death, 1 month 
cycle 
Treatment 
received 
until 
disease 
progression. 
Subsequent 
treatment 
not 
considered 
in model. 
ICER € 
30,277/QALY  
and  € 
18,568/LY 
Changing the 
projected OS 
was the most 
influential 
factor on the 
ICER 
NICE 
Technology 
Appraisal 428 - 
Pembrolizuma
b, 
Merck Sharp & 
Dohme, 2017, 
UK [32] 
Pembrolizumab 
vs docetaxel vs 
nintedanib plus 
docetaxel 
Previously 
treated adults 
with advanced 
NSCLC, 
following 
platinum-
containing 
chemotherapy 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
20 years Cost per 
QALY 
gained 
Partitioned survival 
model with 3 states: 
pre-progression, 
post-progression 
and death, 1 week 
cycle 
All 
treatment 
would not 
go beyond 2 
years. 
Company Base 
Case 1: ICER vs 
docetaxel = £ 
43,351/QALY 
Company Base 
Case 1: ICER vs 
Nin+Doc = £ 
34,997/QALY 
ICER was very 
sensitive to 
duration of 
treatment 
effect, and 
method of OS 
extrapolation 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Company Base 
Case 2: ICER vs 
docetaxel = £ 
49,048/QALY 
Company Base 
Case 2: ICER vs 
Nin+Doc = £ 
23,424/QALY 
Revised 
submission 
Company Base 
Case ICER vs 
docetaxel = £ 
49,063/QALY 
ERG preferred 
ICER is £ 
61,954 /QALY 
NICE 
Technology 
Appraisal 483 
– Nivolumab, 
Bristol Myers-
Squibb, 2017, 
UK [33] 
Nivolumab vs 
docetaxel 
People with 
previously 
treated locally 
advanced or 
metastatic 
(stage IIIB or IV) 
squamous 
NSCLC  
 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
20 years Cost per 
QALY 
gained 
Partitioned survival 
model with 3 states: 
pre-progression, 
post-progression 
and death, 7 day 
cycle 
Proportiona
l hazards 
assumed for 
PFS by 
company. 
Treatment 
received 
until 
Company base-
case: ICER = £ 
85,950/QALY 
ERG base-case: 
ICER = £ 
132,989/QALY 
These ICERs do 
not include a 
PAS and are 
ICER was 
sensitive to 
parametric fit, 
hazard ratio, 
body weight 
and discount 
rates 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
disease 
progression. 
from first 
company 
submission. 
FAD ICERs: 
Committee 
preferred:  £ 
50,014/QALY 
(including a 
PAS, and based 
on a later 
company 
submission) 
NICE 
Technology 
Appraisal 484 
– Nivolumab, 
Bristol Myers-
Squibb, 2017, 
UK [34] 
Nivolumab vs 
docetaxel 
(also compared 
with nintedanib 
plus docetaxel) 
Target: Adults 
with locally 
advanced or 
metastatic non-
squamous 
NSCLC after 
prior 
chemotherapy 
NICE 
recommendatio
n: as above but 
their tumours 
must be PD-L1 
positive 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
20 years Cost per 
QALY 
gained 
Partitioned survival 
model with 3 states: 
pre-progression, 
post-progression 
and death, 7 day 
cycle 
After 18.4 
years, all 
patients in 
PFS were 
assumed 
cured, and 
subject to 
background 
mortality. 
Subsequent 
treatment 
not 
considered 
in model. 
Nivolumab vs 
Ddocetaxel: 
ICER = £ 
103,589/QALY, 
inc costs = £ 
75,452, inc 
QALY = 0.73 
Nivolumab vs 
Nin+Doc: ICER 
= £ 
126,861/QALY, 
inc costs = 
62,598, inc 
QALY = 0.49 
Unclear if these 
results include 
ICER was most 
sensitive to 
choice of 
parametric 
fits, body 
weight and 
discount rates 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
any discount 
on drug prices. 
ERG ICER vs 
Doc= £ 
165,234/QALY 
FAD ICER: £ 
49,160 
NICE  
Technology 
Appraisal 520 
–
Atezolizumab, 
Roche, 2018, 
UK [35] 
Atezolizumab vs 
docetaxel vs 
nintedanib plus 
docetaxel 
People with 
advanced or 
metastatic 
NSCLC who had 
previously been 
treated with 
chemotherapy 
Economic 
analysis from 
NHS/PSS 
perspective, 
with a 3.5% 
discount rate 
25 years Cost per 
QALY 
gained 
Partitioned survival 
model with three 
health states: on 
treatment, off 
treatment and 
dead, 3 week cycle 
The 
company 
assumes 
that the 
treatment 
effect 
remains for 
the 
duration of 
the 
economic 
model.  
A cure 
fraction is 
applied for 
patients 
with stable 
disease. 
Company base-
case  
(list prices): 
 vs Docetaxel 
ICER = £ 
72,356/QALY  
vs Nin+Doc 
ICER = £ 
56,100/QALY 
ERG preferred 
(list prices):  
Vs docetaxel 
ICER = £ 
170,500/QALY 
Vs Nin+Doc 
ICER = £ 
1,170,800/QAL
Y 
Cure fraction 
and choice of 
OS parametric 
curve were the 
most 
influential on 
the ICER 
Aguiar et al., 
2018, South 
America [36] 
Nivolumab and 
pembrolizumab 
and 
Patients with 
advanced NSCLC 
eligible for 
Economic 
analysis from 
payers 
5 years Cost per 
LYG and 
Cost per 
A model-based 
analysis but the 
None Nivo in 
squamous 
No sensitivity 
analyses were 
reported 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
atezolizumab vs 
docetaxel and 
platinum-based 
chemotherapy 
second-line 
treatment in 
either Brazil, 
Argentina or 
Peru 
perspective 
with no 
reported 
discount rate 
QALY 
gained 
model was not 
described in detail 
disease 
patients: 
Brazil ICER = 
US$ 168,100 
/QALY 
Arg ICER = US$ 
224,000/QALY 
Peru ICER = 
US$ 
170,400/QALY 
Nivo in non-
squamous 
disease 
patients: 
Brazil ICER = 
US$ 
217,600/QALY 
Arg ICER = US$ 
297,100/QALY 
Peru ICER = 
US$ 
221,000/QALY 
Pembro in PD-
L1>1% 
patients: 
Brazil ICER = 
US$ 
131,600/QALY 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Arg ICER = US$ 
218,300/QALY 
Peru ICER = 
US$ 
131,100/QALY 
 
No results for 
atezolizumab 
were reported 
Guirgis, 2018, 
unclear setting 
[37] 
Atezolizumab, 
nivolumab, 
pembrolizumab
vs docetaxel 
Patients with 
advanced 
second line 
NSCLC. 
Unclear 1 year Cost per 
LYG, 
relative 
value. 
Crude retrospective 
study using external 
data. 
Used 
median OS 
and prices 
published 
by parent 
companies.  
ICER nivolumab 
vs doc in  
squamous = 
US$ 
488,524/LYG  
ICER nivolumab 
vs doc in non-
squamous = 
US$ 
558,326/LYG 
ICER 
atezolizumb vs 
doc = US$ 
618,244/LYG 
ICER 
pembrolizuma
b vs doc in PD-
L1 >1% = US$ 
1,490,729/LYG 
 
No sensitivity 
analyses were 
performed. 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Shafrin et al., 
2018, Canada 
[38] 
Nivolumab vs 
docetaxel 
Patients with 
stage IIIB or IV 
squamous-cell 
NSCLC who had 
disease 
recurrence after 
one prior 
platinum-
containing 
regimen 
Economic 
analysis 
exploring 
different 
perspectives, 
with a 5% 
discount rate  
10 years Cost per 
QALY 
gained 
Extension to 
existing partitioned 
survival model (see 
Goeree et al.) 1 
week cycle 
OS and PFS 
based on 
Goeree et 
al. 
Traditional 
payer ICER = 
CAD$ 
151,560/QALY 
 
Traditional 
societal ICER = 
CAD$ 
141,344/QALY 
 
Broad societal 
ICER = CAD$ 
80,645/QALY 
Varying the 
value of a 
QALY and 
insurance 
value were the 
most 
influential on 
the net 
monetary 
benefit. Effects 
on ICER were 
not explored 
Zhu et al., 
2018, China 
[39] 
Afatinib vs 
Erlotinib 
Patients with 
advanced 
squamous lung 
cancer who 
progressed after 
at least four 
cycles of 
platinum 
containing 
chemotherapy 
Economic 
analysis from 
Chinese 
healthcare 
system 
perspective, 
with a 5% 
discount 
rate. 
10 years Cost per 
QALY 
gained 
Authors state it is a 
Markov model, but 
we believe it is a 
partitioned survival 
model from the 
description. 
OS, PFS and 
utility data 
come from 
LUX-Lung 8 
trial, 
without 
adaptation. 
ICER = ¥ 
109,429/QALY 
 
Net monetary 
benefit 
estimates 
were sensitive 
to values of OS 
and PFS 
parameters, 
and to the cost 
of the post-
progression 
health state. 
Effects on ICER 
were not 
explored 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
Gao et al., 
2019, Australia 
[40] 
Nivolumab vs 
docetaxel 
Patients with 
advanced or 
metastatic 
squamous 
NSCLC who 
progressed on 
or after 
platinum-based 
chemotherapy. 
Economic 
analysis from 
Australian 
healthcare 
system 
perspective 
with 3% 
discount rate 
6 years Cost per 
LYG and 
Cost per 
QALY 
gained 
Used both a Markov 
model and a 
partitioned survival 
analysis, both with 
three health states: 
on treatment, off 
treatment and 
dead. 
OS and PFS 
data are 
from 
Checkmate 
017 
ICER 
Partitioned 
survival = A$ 
198,862/QALY  
ICER Markov = 
A$ 
220,029/QALY 
Choice of OS 
and PFS curve, 
cost of 
nivolumab and 
time horizon 
were all 
influential on 
ICER. 
Merino 
Almazan et al., 
2019, Spain 
[41] 
Nivolumab vs 
docetaxel 
Patients who 
experienced 
progression 
after first-line 
therapy for 
advanced or 
metastatic 
NSCLC and were 
treated with 
nivolumab 
between 
January 2016 
and July 2017 
Economic 
analysis of 
data from 15 
hospitals in 
Spain 
Maximu
m of 19 
months 
of 
follow-
up. 
Cost per 
LYG 
Retrospective 
analysis, no model. 
Docetaxel 
performanc
e was 
estimated 
by applying 
a hazard 
ratio of 0.73 
for non-
squamous 
patients and 
0.59 for 
squamous 
patients. It 
is unclear 
how it was 
applied. 
ICER = € 
110,026/LYG 
The ICER was 
sensitive to 
the value used 
for the hazard 
ratio. No other 
sensitivity 
analysis were 
conducted. 
Ondhia et al., 
2019, Canada 
[42] 
Atezolizumab vs 
docetaxel vs 
nivolumab  
Patients with 
advanced NSCLC 
who progressed 
after first-line 
Cost utility 
analysis from 
Canadian 
healthcare 
10 year PFS and 
OS 
Partitioned survival 
model with three 
health states: on 
treatment, off 
Time 
varying 
hazard 
ratios were 
ICER of 
atezolizumab 
vs docetaxel: 
Time horizon, 
source of 
hazard ratio 
and treatment 
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Author, year, 
location 
Intervention/ 
Comparator 
Population/ 
Disease 
Study 
characteristi
cs (study 
design, 
perspective, 
setting, 
discounting) 
Time 
Horizon 
Outcome
s 
Analysis/model 
type 
Key 
Assumption
s 
Main Findings Most 
Influential 
Parameters 
platinum-
doublet 
chemotherapy 
perspective 
with 
1.5% 
discount rate 
treatment and 
dead. 
obtained 
from a 
fractional 
polynomial 
network 
meta-
analysis. 
CAD$ 
142,074/QALY. 
Atezolizumab 
dominated 
nivolumab. 
duration were 
the most 
influential 
parameters. 
Abbreviations and Acronym: AG, assessment group; Arg, Argentina; BSC, best supportive care; CAD, Canadian dollar; CEA, cost-effectiveness analysis; CHf, Swiss franc; 
Doc, Docetaxel; ECOG, Eastern Cooperative Oncology Group; ERG, evidence review group; FAD, final appraisal document; ICER, incremental cost-effectiveness ratio; inc, 
incremental; LY, Life-years; LYG, life-years gained; NHS, National Health Service; NICE, National Institute of Health and Care Excellence; Nin, Nintedanib; Nivo, nivolumab; 
NSCLC, non-small cell lung cancer; OS, overall survival; PAS, patient access scheme; PD-L1, programmed death-ligand 1; Pembro, pembrolizumab; PFS, progression-free 
survival; PS, performance status; PSA, probabilistic sensitivity analysis; PSM, partitioned survival model; PSS, personal social services; QALY, quality adjusted life-years 
gained. 
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3.2 Summary of modelling techniques, clinical inputs, resource use and costs, and outcome measures 
3.2.1 Structure 
Eight studies did not use a formal economic model for their analysis, and used benefits observed 
from a clinical trial or registry data [13, 14, 21-23, 26, 37, 41]. The structure of the economic models 
in all other studies were clearly stated and were consistent, all reflecting the progressive nature of 
NSCLC. Most model-based studies used the same three health states (progression-free, post-
progression and death) to distinguish between patient quality of life and associated costs, but two 
used alternative health states [15, 35]. The most commonly used models were partitioned-survival 
models [16, 24, 25, 28-36, 39, 40, 42] and Markov models [15, 18-20, 27, 28, 40]. Carlson et al. 
appeared to use a decision tree [17], whilst the type of model used was unclear for two studies [36, 
38]. All studies but one [27] with model-based cost-effectiveness analyses clearly stated the time 
horizon, which ranged from 2 years [16-19] to 25 years [35]. The study that did not provide a specific 
time horizon did state that it used a ‘lifetime’ time horizon [27]. The choice of economic model was 
rarely well justified and it was often unclear why a study opted for their implemented approach. It is 
possible that the modelling approach may influence the outcome and so it is important to consider 
which approach is best suited to answer the question with the data available [43]. Goeree et al. and 
Gao et al. both compared Markov and partitioned survival approaches. The results from Goeree et 
al. were similar for both models, though for one treatment comparison the ICER did vary by CAD$ 
1,200/QALY based only on the modelling approach [28].  The results of Gao et al. produced ICERs 
that differed by over A$ 20,000/QALY [40].  
3.2.2 Data 
The source of clinical and cost inputs was reported and adequate for all studies, except one [37] 
where the sources were not referenced. All studies which included medical resource use in their 
analysis clearly stated the source of resource use information used.  The choices of outcome 
measure were clearly stated and always consistent with model structure (OS and PFS). All but two 
studies [37, 41] stated the perspective from which their economic analysis was conducted, with all 
other studies including costs from the perspective of the relevant healthcare system or funder. Ten 
studies reported also considered costs related to personal social services [15, 18, 19, 24, 25, 29, 32, 
34, 35, 38].  
 
3.2.3 Uncertainty and assumptions 
Almost all studies explored potential sources of uncertainty in their analysis, with three studies not 
performing any sensitivity analyses [36, 37, 41]. Uncertainty was most commonly explored through 
one-way sensitivity analyses (OWSA) (n=23), probabilistic sensitivity analyses (PSA) (n=22), and 
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scenario analyses (n=21). Sixteen studies included all three approaches [18-20, 22-25, 27, 29-35, 40], 
however there was inconsistency over the parameters included in the sensitivity analyses. 
The most influential factors observed in multiple studies were the survival related parameters, 
including hazard ratios, parametric curves and cure proportions, and utility values, however not all 
studies were exhaustive in their inclusion of variables within their sensitivity analyses. No study 
comprehensively addressed all potential sources of uncertainty. 
The majority of assumptions were related to patient survival, assuming either equal survival or 
proportional hazard rates between different interventions. Additional assumptions made within 
studies were related to the utility values, treatment duration or the impact of later lines of 
treatment. Many studies did not report any assumptions made within their economic analysis. Only 
the technology appraisals presented analyses where the impacts of the main assumptions were 
assessed through the application of alternative assumptions.  
 
3.2.4 Economic Results 
Table 1 summarises the characteristics of included studies. Docetaxel was the most commonly 
considered intervention, with only three studies not including it as an intervention of interest or 
comparator [23, 31, 39]. The majority of studies reported results in terms of cost per QALY as well as 
cost per LYG, with six reporting results in terms of LYG alone [13, 14, 23, 26, 37, 41] and two only in 
terms of QALYs [38, 39]. One study did not present any form of cost-effectiveness ratio, due to the 
interventions being indistinguishable in their benefits [21]. 
 
The majority of studies were from Western Europe (UK=11 [14, 15, 18, 19, 24, 25, 29, 32-35], 
France=2 [22, 31], Spain=3 [20, 26, 41], Portugal=1 [16], Switzerland=1 [27]) with the remaining 
studies based in the Americas (Canada=7  [13, 17, 21, 23, 28, 38, 42], USA=2 [30, 37], South 
America=1 [36]), China (n=1) [39] and Australia (n=1) [40]. 
Most studies (n=19) were sponsored by pharmaceutical companies with 11 studies not declaring any 
pharmaceutical support [18, 21-24, 26, 27, 36, 37, 40, 41]. 
 
3.2.5 Patient Characteristics 
All analyses focussed on the same general population (patients on second line or later treatment for 
previously treated metastatic or advanced NSCLC), however there was slight variation in the staging 
of patients with two studies including stage IIIA patients in addition to IIIB and IV stage patients [15, 
16], and five studies not reporting on the disease stage of patients [14, 27, 36, 37, 41]. Aside from 
Carlson et al. [17], (stage III and IV)  and technology appraisal 403 (stage IV only) [29], all other 
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studies considered stage IIIB and IV patients. Restrictions on ECOG performance status was also 
reported by 13 studies, with restrictions varying across 0 to 1 [29, 33, 34, 40, 42], 0 to 2 [13-15, 22, 
39, 41], and 0 to 3 [19, 24]. Two analyses focussed on non-squamous disease [20, 34], six on 
squamous disease [28, 31, 33, 38-40], with the remaining studies not distinguishing between NSCLC 
subtypes. Nine studies presented results by subgroup, with the range of subgroups considered: 
ECOG score [15, 16], line of treatment [16], squamous/non-squamous disease [29, 36, 37], EGFR 
negative/unknown [24, 34], programmed death-ligand 1 (PD-L1) expression [27, 34, 36, 37] and 
adenocarcinoma [29, 32].  
3.2.6 Survival  
 A range of approaches were used to modelling the clinical effectiveness of the interventions.  
Retrospective studies used the mean or median survival observed from their relevant source of data.  
Meanwhile the Markov models assumed a constant hazard to calculate the transition rates between 
its health-states. An increasingly popular approach was to use a partitioned survival model where 
the progression-free survival (PFS) and overall survival (OS) curves are modelled parametrically, 
either jointly to multiple trial arms, or independently. This provides the number of patients in the 
progression-free and death health states. The number of patients in the post-progression heath 
state is then calculated as the difference between the PFS and OS curves. For indirect comparisons, 
hazard ratios were estimated and applied to parametric models.  
 
3.3 Quality assessment 
We assessed the reporting quality of 30 studies using both the CHEERS and Philips checklists, 
summaries of which can be found in tables 2 and 3 respectively. The reporting quality was generally 
high, with the majority of items on both checklists fulfilled by over 85% of studies.  All studies 
reported their characteristics such as setting, perspective, the comparators and measures of 
effectiveness. There were several key areas for improvement: inclusion of additional relevant 
comparators, presentation of justification when multiple sources of information were available, 
consideration of subgroups and other sources of heterogeneity and discussions of the 
generalisability of the findings. It was apparent that half-cycle corrections were not used in the 
majority of models, but given the short cycle length used, this was not thought to detract from the 
quality.  
 
4.  Discussion 
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This review demonstrated that there are a number of different approaches to performing an 
economic analysis within the scope of assessing therapeutic options for advanced/metastatic NSCLC. 
Whilst in the older studies economic evaluations of clinical trials were very popular, as computing 
power and awareness of modelling techniques increased, Markov models and partitioned survival 
models have become more common. This likely reflects better awareness of modelling approaches 
combined with superior treatments and healthcare which prolong patient survival. Whilst two-years 
of trial follow-up may have been sufficient to observe all survival events twenty years ago, with time 
horizons of over twenty years in the more recent articles, it is clear that some prediction and 
accompanying assumptions are necessary.    
Whilst all of the studies provided a comparison to a suitable and relevant intervention, often the 
comparator was not recently licensed. Whilst this may be explained by the rapidly evolving nature of 
healthcare and interventions, there may also be a bias when selecting comparators to ensure new 
interventions look as good as possible [44]. It is important to compare to the current best 
treatments, to ensure patients receive the best care and that a healthcare system receives optimal 
value for money. 
The complexity of the evaluations varied greatly, with some making assumptions such as equal 
efficacy between treatments with limited or no direct comparative evidence, whilst others creating 
de novo economic models.  
Alongside the shift towards partitioned survival modelling is the consideration of quality of life, 
through quality-adjusted life years (QALYs), rather than length of life alone, life years (LYs). This 
reflects a change in attitude of decision makers that the quality of life of patients should be 
considered with the length of life, and that treatments which offer life extending benefits but with 
heavy side effects may not be in the interest of patients.  
There was a general trend of increasing time horizon as studies became more recent, suggesting that 
improved healthcare is improving the life expectancy of NSCLC patients. 
It was rare for studies that were not directly related to a technology appraisal to consider and 
explore sources of uncertainty within their economic evaluation. Those that did explore uncertainty 
performed either probabilistic sensitivity analyses, allowing for uncertainty around multiple factors 
feeding into the economic model, or explored scenario / one-way sensitivity analyses, using 
confidence intervals or other parameter values to capture uncertainty in individual parameters. 
A challenge of this systematic review was how to extract information from the evaluations directly 
from a NICE technology appraisal, as there can often be multiple opinions from the company, the 
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ERG and even the committee themselves. Opinions too may change during an appraisal with the 
availability of more information. It was sometimes challenging for our review team to select the 
most useful information for inclusion in this review, and so we focused our extraction on the first 
available set of committee papers. 
It is plausible that publication-based evaluations may also be hampered from mistakes in modelling 
or bias(es) that are not identified, without the level of critique that comes with a NICE technology 
appraisal. A further limitation is that we have not specifically captured the quality of the 
methodology within each paper, having focused on the reporting quality, nor completed a formal 
assessment of transferability of each study.  
The geographical range of studies showed that the cost-effectiveness of treatments is an important 
factor in the decision making process in many countries around the world. The transferability of all 
the results is difficult to ascertain because what may be cost-effective in one setting is not 
necessarily cost-effective in another setting. Different countries have different healthcare priorities 
and budgets with which to accomplish them. Indeed, the relative cost-effectiveness of two 
interventions may vary between countries due to differences in administration, cost and availability 
of later line treatments, and discounts offered by the manufacturer on the interventions. Whilst 
aspects of the different studies may be generalisable to other settings, the different currencies, 
decision makers and funders make it difficult to transfer conclusions of cost-effectiveness. 
It is difficult to draw conclusions over which treatment is the most cost-effective, not least because 
manufacturers often offer a discount on the list price for their interventions. These discounts are 
confidential, and so economic analyses published in journals are based on list prices, with only 
analyses from decision-making processes (such as NICE technology appraisal documentation) 
including the actual prices paid. Whilst this suggests that technology appraisals may be the more 
informative source of information, however, part of the cost-effectiveness results are often 
redacted. Whilst the ICER is usually available, detailed breakdowns of costs and benefits are 
withheld to prevent back-calculation of the discount.  
Whilst all licensed interventions have had their cost-effectiveness assessed against at least one 
comparator, there has been no published work comparing them simultaneously. This review has 
highlighted an unmet area of research. In order to ensure health services receive best value-for-
money, it is important to perform such an evaluation.  
Both partitioned survival models and Markov models have their limitations. A Markov model can 
cope with any number of health states, and allow for transitions from any one state to any other. 
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However, these transition probabilities will often be modelled in a simple manner and assumed to 
be constant over time. It becomes harder to obtain reliable estimates for the transitions when 
modelling more health states.  
Meanwhile, a partitioned survival model can more easily capture hazards which vary over time, 
utilizing a wide range of parametric survival curves, but requires the health states to be ordered with 
transition between them only allowed in one direction. Whilst this may be adequate at present for 
progressive diseases such as NSCLC, it is unclear whether they will always be suitable for capturing 
the benefits of future treatments. As demonstrated by Goeree et al. [28], the approaches can lead to 
almost identical results. It is likely that for the majority of interventions considered in this review, 
the decision to analyse using either a partitioned survival model or a Markov model is relatively 
inconsequential on the outcome. However, for more recent interventions, such as immunotherapies 
which claim to be very effective in certain patients, both approaches can fall short of accurately 
capturing the patient pathway, without adjustment. For example two of the most recent technology 
appraisals reported altering the basic partitioned survival framework to assume that certain patients 
were cured or at a reduced risk of a cancer related death [34, 35]. Further developments in the 
treatment for advanced NSCLC may require further adjustments to be made to the traditional 
modelling approaches, but we certain of the suitability of any adjustments without supporting data.  
Whilst all aspects of a cost-effectiveness analysis should be scrutinised, survival extrapolations 
should be given extra attention given that they were highly influential to cost-effectiveness results in 
a number of studies. If an intervention was wrongfully demonstrated to be cost-effective, and 
became a benchmark for future treatments to be assessed against, this could result in more heavily 
stretched healthcare budgets. With model time horizons increasing alongside pressure from public 
and patients demands to get rapid access to treatments, survival extrapolations will only become 
more influential. In the NICE technology appraisals, it was common for the ERG to disagree with the 
company’s survival related assumptions. It raises questions over the reliability of the extrapolations 
in other published studies, as it is unlikely that the peer-review process contained the same rigour as 
a NICE technology appraisal. A recent review of NICE technology appraisals showed that in only 7% 
of appraisals did the ERG agree with all the major survival-related assumptions [45]. This 
demonstrates the need for well-established guidelines to reduce the extent to which survival 
extrapolations are based on subjective assumptions. Methods detailing the selection of 
extrapolation approach should be clearly described, with all supporting material provided in 
appendices.  
We recommend that an economic model should accurately capture all of the major phases of a 
patient’s pathway. The framework, inputs and assumptions should be clearly stated and referenced. 
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Inputs should be relevant to the population and setting where possible. The potential effects of key 
areas of uncertainty should be explored through OWSAs, PSAs and scenario analyses. Supporting 
evidence related to decisions around influential assumptions, such as choice of survival 
extrapolation, should be presented as supplementary material to maximise transparency and 
reproducibility.  
This approach could be used to undertake a cost-effectiveness comparing all currently licensed drugs 
used for EGFR and ALK negative advanced/metastatic NSCLC, and could be extended to other 
disease areas. 
 
5. Conclusion 
This review summarises the range of methods used in assessing the cost-effectiveness of licensed 
interventions for advanced/metastatic NSCLC. The structure of the models was generally consistent. 
The modelling of overall survival is routinely one of the most influential factors on the cost-
effectiveness conclusions and often contains considerable uncertainty due to the short follow-up of 
the most recent studies used in the economic evaluations. Transparency over survival extrapolation 
approaches is critical to reduce bias in cost-effectiveness analyses. 
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Table 2: Summary of Results from CHEERS Checklist 
Question N(YES)/N(Applic
able) [%] 
Question N(YES)/N(Applic
able) [%] 
Title 28/30 [93%] Estimating resources and 
costs 
29/30 [97%] 
Abstract 22/23 [96%] Currency, price date, and 
conversion 
23/30 [77%] 
Background/objectives 30/30 [100%] Choice of model 19/22 [86%] 
Target population and 
subgroups 
30/30 [100%] Assumptions 22/25 [88%] 
Setting and location 30/30 [100%] Analytical methods 26/29 [90%] 
Study perspective 28/30 [93%] Study parameters 27/30 [90%] 
Comparators 30/30 [100%] Incremental costs and 
outcomes 
30/30 [100%] 
Time horizon 23/26 [88%] Characterising 
uncertainty 
28/30 [93%] 
Discount rate 19/25 [76%] Characterising 
heterogeneity 
7/30 [23%] 
Choice of health 
outcomes 
30/30 [100%] Study findings, 
limitations, 
generaliseability and 
current knowledge 
6/30 [20%] 
 
Measurement of 
effectiveness 
30/30 [100%] Sources of funding 24/26 [92%] 
Measurement and 
valuation of preference 
based outcomes 
23/27 [85%] Conflicts of interest 25/26 [96%] 
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Table 3: Summary of results of Phillips Checklist 
Question N(YES)/N(Appl
icable) [%] 
Question N(YES)/N(Appl
icable) [%] 
Is there a clear statement of the 
decision problem? 
30/30 [100%] Where choices have been made 
between data sources are these 
justified appropriately? 
8/18 [44%] 
Is the objective of the model 
evaluation and model specified 
and consistent with the stated 
decision problem? 
22/22 [100%] 
Where expert opinion has been 
used are the methods described 
and justified? 
10/17 [59%] 
Is the primary decision maker 
specified? 
15/30 [50%] Is the choice of baseline data 
described and justified? 
29/30 [97%] 
Is the perspective of the model 
stated clearly? 
22/22 [100%] Are transition probabilities 
calculated appropriately? 
16/21 [76%] 
Are the model inputs consistent 
with the stated perspective? 
21/22 [95%] Has a half-cycle correction been 
applied to both costs and 
outcomes? 
10/22 [45%] 
Is the structure of the model 
consistent with a coherent 
theory of the health condition 
under evaluation? 
20/22 [91%] 
If not, has the omission been 
justified? 
2/12 [17%] 
Are the sources of the data used 
to develop the structure of the 
model specified? 
20/22 [91%] Have the methods and 
assumptions used to 
extrapolate short-term results 
to final outcomes been 
documented and justified? 
19/21 [90%] 
Are the structural assumptions 
reasonable given the overall 
objective, perspective and 
scope of the model? 
21/22 [95%] 
Are the costs incorporated into 
the model justified? 
22/22 [100%] 
Is there a clear definition of the 
options under evaluation? 
30/30 [100%] Has the source for all costs been 
described? 
26/27 [96%] 
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Have all feasible and practical 
options been evaluated? 
11/30 [37%] Have discount rates been 
described and justified given 
the target decision maker? 
21/22 [95%] 
Is there justification for the 
exclusion of feasible options? 
6/19 [32%] Are the utilities incorporated 
into the model appropriate? 
21/23 [91%] 
Is the chosen model type 
appropriate given the decision 
problem and specified casual 
relationships within the model? 
20/22 [91%] 
 Is the source of utility weights 
referenced? 
19/23 [83%] 
Is the time horizon of the model 
sufficient to reflect all 
important differences between 
the options? 
20/22 [91%] If data have been incorporated 
as distributions, has the choice 
of distributions for each 
parameter been described and 
justified? 
9/20 [45%] 
Do the disease states (state 
transition model) or the 
pathways (decision tree model) 
reflect the underlying biological 
process of the disease in 
question and the impact of 
interventions? 
21/22 [95%] 
If data are incorporated as point 
estimates, are the ranges used 
for sensitivity analysis stated 
clearly and justified? 
22/26 [85%] 
Is the cycle length defined and 
justified in terms of the natural 
history of disease? 
20/22 [91%] Has heterogeneity been dealt 
with by running the model 
separately for different sub-
groups? 
7/30 [23%] 
Are the data identification 
methods transparent and 
appropriate given the objectives 
of the model? 
22/22 [100%] Have the results been 
compared with those of 
previous models and any 
differences in results explained? 
14/30 [47%] 
 
 
